CN Patent

CN121398832A — 用于药物疗法的司美格鲁肽

Assigned to Novo Nordisk AS · Expires 2026-01-23 · 0y expired

What this patent protects

本发明涉及GLP‑1受体激动剂司美格鲁肽在用于治疗射血分数保留型心力衰竭（HFpEF）的药物疗法中的用途。

USPTO Abstract

本发明涉及GLP‑1受体激动剂司美格鲁肽在用于治疗射血分数保留型心力衰竭（HFpEF）的药物疗法中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN121398832A
Jurisdiction
CN
Classification
—
Expires
2026-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.